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therapy is ineffective. Consequently, the num-
ber of LAAO procedures performed is steadily 
increasing each year.3
Various studies show that LAAO is associat-
ed with good short- and midterm results, even 
in high -risk patients.1,2,6‑8 However, these studies 
mainly focus on stroke risk reduction and mor-
tality. There are no recent analyses of the causes 
of death and clinical outcomes of patients un-
dergoing LAAO.
The primary aim of this study was to evalu-
ate survival free of any serious adverse events 
and of any -cause death in midterm (>2 years) 
IntroductIon More than 10 years after 
the first -in -man case, left atrial appendage occlu-
sion (LAAO) continues to revolutionize the man-
agement of stroke prevention in patients with 
nonvalvular atrial fibrillation (AF) and has be-
come, over time, a routinely performed proce-
dure worldwide.1‑4 In 2012, the European So-
ciety of Cardiology guidelines recommended 
LAAO for patients with AF in whom oral anti-
coagulation (OAC) is contraindicated (indica-
tion IIb, level of evidence B).5 Recently, the in-
dication for LAAO in some European countries 






















Background Left atrial appendage occlusion (LAAO) is a safe and effective alternative for stroke 
prevention in patients with atrial fibrillation (AF). However, there is little literature on the exact causes 
of death and adverse events during follow ‑up after LAAO.
aims The primary aim of this study was to evaluate survival free of any serious adverse events and of any‑
‑cause death in midterm follow ‑up. The secondary aims were to analyze causes of mortality and further 
hospitalization as well as adverse events, thromboembolism, and bleeding risk reduction during follow ‑up.
methods A retrospective, single ‑center study was performed in 84 consecutive patients with AF who 
underwent LAAO with endocardial occluders. The mean (SD) CHADS2 score was 3.5 (1.1), CHA2DS2‑VASc 
score, 5.0 (1.5), and HAS ‑BLED score, 4.4 (0.9). After LAAO, dual 6‑month antiplatelet therapy and then 
lifelong aspirin monotherapy was recommended. Mean (SD) follow ‑up was 25.3 (13.2) months with 
an accumulated total follow ‑up of 174.6 patient ‑years.
results The annual mortality rate was 12.02%. More than half of deaths (57%) were due to noncardiovascular 
causes with leading malignancy. Survival at the end of the periprocedural period was 98.8%, at 3 months, 
97.6%, at 6 months, 95.2%, at 12 months, 86.5%, at 18 months, 85.1%, and at 24 months, 80.6%. The average 
annual thromboembolic event rate was 2.87%. The most common adverse event was severe bleeding with 
an annual rate of 6.3% (3 cases while receiving dual antiplatelet therapy and 6 cases while receiving aspirin).
conclusions The majority of deaths were not related to stroke in patients with AF after LAAO. Mortality 
in first 2 years following the procedure was predominantly from noncardiovascular causes.
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the performed actions were constantly moni-
tored using 2- dimensional and 3- dimensional 
TEE. During the first stage of the procedure, 
this examination was particularly useful for 
determining the optimal site of transseptal 
puncture. During the subsequent stages, TEE 
was used to establish the dimensions of the left 
atrial appendage, control the implantation 
process, and provide ultimate confirmation 
that the occluder system is in the proper posi-
tion. Once the implant was placed in the LAA, 
angiography and echocardiography were per-
formed to check device positioning, LAA seal-
ing and impingement on surrounding struc-
tures. A gentle tug test was performed to en-
sure device stability.1,2
Postprocedure anticoagulation After device 
implantation, it was recommended to administer 
dual antiplatelet therapy (DAPT) for 6 months 
(75-mg aspirin once daily and 75-mg clopido-
grel once daily) and after that lifelong aspirin 
monotherapy (75-mg once daily).
Follow ‑up Hospital follow -up visits were per-
formed at 3 months and 6 months after the pro-
cedure. To evaluate the presence of postproce-
dure leak, TEE was performed in each patient. 
Telephone follow -up calls and analysis of hos-
pital records were performed at 12, 24, 36, and 
42 months after LAAO. Data collection and ad-
verse event reporting were completed by the phy-
sician who performed the procedure.
Adverse events, serious adverse events, and 
mortality The study variables were included 
in a dedicated database. Adverse events were re-
ported during follow -up visits based on the Mu-
nich LAA consensus document.10 We recorded 
mortality (cardiovascular, noncardiovascular, 
procedural, immediate procedural), thromboem-
bolic events (stroke, transient ischemic attack 
[TIA], systemic embolism), and life -threatening, 
disabling, or major bleeding. For this study, we 
classified heavy bleeding as life threatening, or 
disabling, or major bleeding (Bleeding Academ-
ic Research Consortium type 3a bleeding). Addi-
tionally, each patient’s hospitalization and cause 
of admission were reported as adverse events. 
Researchers had access to the medical records 
from each patient’s hospitalization.
Mortality definitions were based on those 
included in the Valve Academic Research Con-
sortium-2 consensus document.11 All deaths 
were reported with timing relative to the in-
dex procedure as well as the underlying causes. 
Mortality was classified into 3 categories: car-
diovascular, noncardiovascular, and proce-
dural. Procedural mortality was defined as 
mortality between implantation and hospi-
tal discharge or between implantation and 
day 30 of follow -up.10
follow -up. The secondary aims were to analyze 
causes of mortality, further hospitalizations, ad-
verse events, thromboembolism, and bleeding 
risk reduction during follow -up.
Methods A  retrospective, single -center 
study was performed in 84 consecutive pa-
tients with nonvalvular AF who underwent 
LAAO with the AMPLATZER Amulet (Abbott, 
St. Paul, Minnesota, United States) or The LAm-
bre (Lifetech Scientific Corp., Shenzhen, China) 
endocardial left atrial appendage (LAA) occlud-
ers between March 2015 and December 2018. All 
procedures were performed by 2 operators who 
underwent training using a simulation model 
that allowed the operator understand and prac-
tice the various steps of procedure using both 
types of occluders (AMPLATZER and LAmbre). 
Inclusion and exclusion criteria for the Amulet 
and the LAmbre LAAO procedures have been de-
scribed previously.1,2,9 We collected data on pa-
tient demographics, medical history, stroke 
risk (CHADS2 score and CHA2DS2-VAS score), 
and bleeding risk (HAS -BLED score).
Implantation procedure All patients un-
derwent transesophageal echocardiography 
(TEE) 24 hours before the procedure in order 
to exclude the presence of thrombus in the left 
atrial appendage. The patients were hydrated in 
order to optimize atrial filling. The procedure 
was performed under general anesthesia and 
antibiotic protection (2nd generation cephalo-
sporin) using echocardiographic -fluoroscopic 
fusion system, EchoNavigator (Philips Inc., 
Amsterdam, Netherlands). Heparin was ad-
ministered in 2 doses of 100 U/kg bw: first, 
after the introduction of the catheter into 
the lumen of the superior vena cava; second, 
after transseptal puncture and the introduc-
tion of the catheter into the lumen of the left 
atrium. Mean left atrial pressure was mea-
sured, and 10 mm Hg was assumed as the val-
ue allowing for continuation of the procedure. 
Using contrast fluoroscopy, the left atrial ap-
pendage was visualized selectively in order to 
evaluate the anatomy. Angiography was per-
formed using RAO 20°, caudal 20° and RAO 
30°, cranial 10° projections. Simultaneously, 
whAt’s new?
Previous studies on left atrial appendage occlusion (LAAO) were mainly focused 
on stroke risk reduction and mortality. There are no recent analyses of 
the causes of death and clinical outcomes of patients undergoing LAAO. 
Therefore, we evaluated survival free of any serious adverse events and of 
any ‑cause death in midterm follow ‑up after LAAO. More than half of deaths 
(57%) were not related to stroke but were due to noncardiovascular causes 
with leading malignancy. The most common adverse event was severe bleeding 
with an annual rate of 6.3%.
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thromboembolism and bleeding reduc‑
tion calculation As in our previous study,7,8 
the efficacy of the procedure in the prevention 
of thromboembolic events (stroke, TIA, system-
ic embolism, intraventricular thrombus) was 
calculated by comparing the actual event rate 
to the event rate predicted by CHA2DS2-VASc 
score.5,12,13 Individual patient’s annual risk was 
recorded and the average annual risk for the en-
tire study population was calculated. Thrombo-
embolism reduction was calculated as follows: 
(estimated percent of event rate – actual percent 
of event rate)/estimated percent of event rate.6
Bleeding reduction was assessed with the 
same method as stroke reduction. The total num-
ber of major bleeding events per year was com-
pared with the number of events predicted by 
the HAS -BLED score14: (estimated percent of 
event rate – actual percent of event rate)/esti-
mated percent of event rate.6
statistical analysis Continuous variables 
were analyzed for normal distribution using 
the Shapiro–Wilk test. Data were expressed 
as mean (SD). Categorical variables were ex-
pressed as counts and percentages. The Kaplan–
Meier analysis was performed to estimate sur-
vival over time. Statistical analysis was per-
formed with STATISTICA 12.0 (StatSoft, Tul-
sa, Oklahoma, United States). A 2-tailed P val-
ue of less than 0.05 was considered significant.
results Patient characteristics The LAAO 
procedure was performed in 84 patients with 
a mean (SD) age of 72 (8.4) years. Patients’ base-
line characteristics are summarized in TABLe 1. 
The  mean (SD) CHADS2 score was 3.5 (1.1), 
mean  (SD) CHA2DS2-VAS score was 5.0 (1.5), 
and mean (SD) HAS -BLED score was 4.4 (0.9). Until 
the procedure, 45.2% of patients were taking vita-
min K antagonists, 51.2% were taking direct oral 
anticoagulant, 2.4% an antiplatelet agent, and 1.2% 
received low -molecular -weight heparin. The most 
common indication for LAAO was gastrointestinal 
bleeding which was present in 57.1% of patients.
Procedure In 71.4% of patients (60 cases), 
the AMPLATZER Amulet occluder was used, and 
in 28.6% patients (24 cases) the LAmbre occlud-
er was selected. The procedure was successful in 
98.8% of cases. Procedural or device-related ad-
verse events were noted in 5 of cases (5.9%). In 
1 patient with unsuccessful Amulet device im-
plantation, iatrogenic aortic damage with tam-
ponade occurred and was resolved with surgical 
intervention using a left minithoracotomy ap-
proach. During surgical intervention, the LAA 
was closed with an epicardial AtriClip device 
(AtriCure, Mason, Ohio, United States). Two pa-
tients developed tamponade 2 days after the pro-
cedure: first due to damage to the pulmonary 
Table 1 Baseline patient characteristics (continued on the next page)
Variable Patients (n = 84)
Age, y Mean (SD) 72 (8.4)
Median (Q1; Q3) 73 (67; 78)
Range 46–87
Sex, female, n (%) 36 (42.9)
CHADS2 score Mean (SD) 3.5 (1.14)
Median (Q1; Q3) 3 (3; 4)
CHA2DS2‑VASc score Mean (SD) 5.0 (1.5)
Median (Q1; Q3) 5 (4; 6)
HAS ‑BLED Mean (SD) 4.4 (0.9)
Median (Q1; Q3) 4 (4; 5)
Successful LAAO, n (%) 83 (98.8)
Comorbidities, n (%)
Congestive heart failure 34 (40.5)
Hypertension 84 (100)
Type 2 diabetes mellitus 35 (41.7)
Previous stroke 33 (39.2)
Vascular disease 54 (64.3)
Alcoholism 2 (2.4)
Indication for LAAO procedure, n (%)
Gastrointestinal bleeding 68 (57.1)
CNS bleeding 6 (7.1)
Respiratory tract bleeding 1 (1.2)
Urinary tract bleeding 2 (2.4)
Thrombus in LAA despite OAC 5 (6)
Stroke/TIA despite OAC 21 (25)
Preprocedure medications, n (%)
Vitamin K antagonists Total 38 (45.2)
Acenocumarol 3 (3.6)
Acenocumarol + ASA 1 (1.2)




Warfarin + ASA 13 (15.5)
Warfarin + ASA + clopidogrel 3 (3.6)
DOACs Total 43 (51.2)
Dabigatran 18 (21.4)
Dabigatran + ASA 2 (2.4)
Dabigatran + ASA+ clopidogrel 2 (2.4)
Rivaroxaban 13 (15.5)
Rivaroxaban + ASA 6 (7.1)
Rivaroxaban + clopidogrel 2 (2.4)
Antiplatelet agents Total 2 (2.4)
ASA 2 (2.4)
LMWH 1 (1.2)
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Mortality and midterm survival All patients 
were included in the follow -up analysis. Mean 
(SD) follow -up was 25.3 (13.2) months with an ac-
cumulated total follow -up of 174.6 patient -years.
The time trend in mortality during follow-
-up and causes of death are listed in TABLe 2. A to-
tal of 21 patients (overall mortality, 21.4%) died 
during the follow -up period: 1 patient (1.2%) dur-
ing the procedural mortality period, 11 (12.4%) 
due to noncardiovascular causes, and 9 patients 
(9.5%) due to cardiovascular causes. The annual 
mortality rate was 12.02%.
Survival at the end of the periprocedural peri-
od was 98.8%, at 3 months, 97.6%, at 6 months, 
95.2%, at 12 months, 86.5%, at 18 months, 85.1%, 
and at 24 months, 80.6%. Survival estimated 
by the Kaplan–Meier analysis for all -cause mor-
tality is presented in FIGURe 1.
The time trend in adverse events (including 
deaths) during follow -up and causes are listed in 
TABLe 3. The most common adverse event was gas-
trointestinal bleeding, reported in 9 patients 
(10.7%). Thromboembolic events were report-
ed in 3 patients (3.6%). Survival estimated by 
the Kaplan–Meier analysis for all -cause adverse 
events is presented in FIGURe 2.
thromboembolism and bleeding risk reduc‑
tion During the study period, the average 
annual thromboembolic event rate was 2.87%. 
There was 1 episode of ischemic stroke (while re-
ceiving DAPT, control TEE showed no evidence 
vein and second due to damage to the pericar-
dial sac. Both cases were resolved by surgical in-
tervention by left minithoracotomy without fur-
ther consequences. There was one sudden cardiac 
death on day 4. There was one case of gastroin-
testinal bleeding on day 11. Additionally, there 
were 4 minor bleeding and vascular complica-
tions at the femoral access site on days 1, 2, 4, and 
10 which resolved with no further complications.
Table 1 Baseline patient characteristics (continued from the previous page)
Variable Patients (n = 84)
Device selected, n (%)
AMPLATZER Amulet 60 (71.4)
LAmbre 24 (28.6)
LAA leak, n (%)
Total 11 (13.1)
Residual flow <1 mm 4 (4.7)
Residual flow 1–3 mm 6 (7.1)
Residual flow >3 mm 1 (1.2)
Abbreviations: ASA, aspirin; CHADS2, congestive heart failure, hypertension, diabetes mellitus, 
age ≥75 years, history of stroke or transient ischemic attack; CHA2DS2‑VASc, congestive heart 
failure, hypertension, age years, diabetes mellitus, history of stroke or thromboembolism, vascular 
disease, age 65 to 74 years, female sex; CNS, central nervous system; DOAC, direct oral 
anticoagulant; HAS ‑BLED, hypertension, abnormal liver function, history of stroke or 
thromboembolism, history of bleeding, age >65 years, use of nonsteroidal anti ‑inflammatory 
drugs, and alcohol abuse; LAA, left atrial appendage; LAAO, left atrial appendage occlusion; LMWH, 
low ‑molecular ‑weight heparin; OAC, oral anticoagulation; TIA, transient ischemic attack
Table 2 Descriptive analysis of causes of death during the procedure and at various stages of follow ‑up
Procedural 
mortality
Follow ‑up, months All







































1 0 2 3 0 1 2 9 (10.7%)
Cause (age 
at death, y)









– SCD (81) SCD (67)
SCD (79)
Abbreviations: AMI, acute myocardial infraction; PCI, percutaneous coronary intervention; SCD, sudden cardiac death
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with no evidence of device thrombus), 1 epi-
sode of pulmonary embolism (while receiving 
aspirin). Additionally, there were 2 episodes of 
thrombus formation on the Amplatzer Amulet 
device (1 case while receiving DAPT and 1 case 
of device thrombus, postprocedure anticoag-
ulation was changed from DAPT to 75-mg as-
pirin once daily and dabigatran 150-mg twice 
daily), 1 episode of TIA (while receiving aspirin, 
control TEE showed mobile interatrial septum 
Table 3 Descriptive analysis of serious adverse events, including mortality, and thromboembolic events during the procedure and at various 
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a Numbers in brackets represent the number of cases with a given adverse event.
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with stroke being the cause of almost 10% of all 
deaths.17 In  clinical trials with 2 years of follow-
-up, death was also the most frequent adverse 
event in anticoagulated patients.17‑19
Patients with contraindications to OAC would 
seem to be the most likely candidates to benefit 
from LAAO, but may have a higher comorbidity 
profile and higher mortality rate that may tem-
per the long -term benefits of LAAO.20 In clini-
cal registries of LAAO, the reported mortality 
rate was 8.4% for the Amulet device 21 and 9.8% 
for the Watchman device.20 In clinical trials with 
long -term data, all -cause mortality has been re-
ported as 10.9% for endocardial devices and 5.5% 
for epicardial devices.8,22 In our study, 1-year 
mortality was 13.1%, which may be perceived as 
high, with overall mortality of 21.4% at 2 years 
of follow -up. However, higher observed mortal-
ity was associated with several clinical factors. 
First of all, our patients had multiple comor-
bidities as evidenced by a higher CHA2DS2-VAS 
score (mean, 5.0) and higher HAS -BLED score 
(mean, 4.4) compared with other LAAO clinical 
trials.7,8,20‑23 In our study, most of the patients 
were older, with a mean age of 72 years, 69% had 
a history of severe bleeding, of whom 7.8% had 
central nervous system bleeding, 39% had a his-
tory of previous ischemic stroke, 40% had heart 
failure, 64% had evidence of vascular disease, 
41% had diabetes mellitus, 100% had hyperten-
sion, and 2.4% were addicted to alcohol. Addi-
tionally, in our study, more than half of deaths 
(57%) were due to noncardiovascular causes with 
malignancy being the leading cause of death. 
Other LAAO clinical registries reported rates of 
noncardiovascular causes of death from 39%21 
to 60%.20 Interestingly, our results are in con-
trast to a study of anticoagulated  patients with 
AF, in which more than half of the patients died 
from cardiovascular causes.17‑19
In our study, there were no deaths caused 
by ischemic stroke or TIA. To the best of our 
knowledge, there are no studies in the litera-
ture that report ischemic stroke or TIA mor-
tality after LAAO. Based on our study results, 
in patients with AF after LAAO, as in anticoag-
ulated patients, the majority of deaths are not 
related to stroke. In clinical registries of anti-
coagulated patients with AF, ischemic stroke is 
the cause of death in 5% to 10% of patients17‑19 
and stroke mortality is similar in patients treat-
ed with either vitamin K antagonists or direct 
oral anticoagulants.18 It should be added that 
the PREVAIL (Prospective Randomized Eval-
uation of the Watchman Left Atrial Append-
age Closure Device in Patients With Atrial Fi-
brillation Versus Long -Term Warfarin Therapy) 
trial reported that rates of ischemic or hemor-
rhagic stroke or cardiovascular or unexplained 
death were similar following LAAO compared 
with warfarin therapy.24 The RE -LY (Random-
ized Evaluation of Long -Term Anticoagulation 
without DAPT) and there was no thrombus on 
the LAmbre device. The annual rate of severe 
bleeding complications was 6.3%. There were 
2 cases of fatal gastrointestinal bleeding and 
9 serious gastrointestinal bleeding episodes re-
quiring hospitalization. Out of those, 6 episodes 
were observed in patients with gastrointestinal 
bleeding history on anticoagulation treatment. 
Estimated thromboembolic risk reduction and 
estimated bleeding risk reduction are presented 
in FIGURe 3. Surgical interventions were required 
in 16.6% of patients: 4.7% in perioperative pe-
riod because of bleeding and vascular compli-
cations at the femoral access, 10.7% in patients 
with gastrointestinal bleeding treated with en-
doscopic management, and 1.2% was the tem-
porary surgical supply of varicose vein bleeding. 
A total of 33.3% of bleeding episodes were ob-
served in the first 6 months after LAAO.
dIscussIon The results of our study sug-
gest that most of the deaths after LAAO are not 
caused by ischemic stroke or TIA but by a non-
cardiovascular cause. Secondly, most hospi-
talization and adverse events after LAAO are 
not caused by thromboembolic events but due 
to severe bleeding. To the best of our knowledge, 
we present the first detailed analysis of causes 
of death and morbidity after LAAO.
Worldwide, AF is the most common cardiac 
arrhythmia with low rates of successful long-
-term treatment.8,15 Atrial fibrillation is inde-
pendently associated with a 1.5- to 2-fold in-
creased risk of all -cause mortality and mor-
bidity.5 Oral anticoagulation significantly re-
duces the risk of death and stroke but may be 
associated with severe or life -threating com-
plications.16 Despite OAC, there is still a signif-
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the use of only a calculated stroke or bleeding risk 
score for analysis. The analyzed group is small. 
We only assessed patients after LAAO in which 
the endocardial devices were employed and our 
results cannot be easily extrapolated to patients 
in whom epicardial devices were employed.
conclusion The majority of deaths are not re-
lated to stroke in patients with AF after LAAO. 
Mortality in the first 2 years following the pro-
cedure was predominantly from noncardiovascu-
lar causes, with 57% of deaths caused by malig-
nancy. The most common adverse event was se-
vere bleeding with an annual rate of 6.3%. How-
ever, in our study the numbers of patients with 
a high bleeding risk (mean [SD], HAS -BLED score 
4.4 [0.9]) or history of severe bleeding were rel-
atively high. Importantly, stroke risk reduction 
and bleeding risk reduction after LAAO were 
comparable with other studies.
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Therapy)25 and ROCKET AF (Rivaroxaban Once 
Daily Oral Direct Factor Xa Inhibition Com-
pared with Vitamin K Antagonism for Preven-
tion of Stroke and Embolism Trial in Atrial Fi-
brillation)26 trials reported that a history of 
stroke, heart failure, and older age were strong 
predictors of stroke -related death. In our study, 
patients were older, with high CHA2DS2-VASc 
scores and previous heart failure. A history of 
previous stroke was observed in almost 40% of 
our patients. Therefore, our cohort had a high 
risk of death caused by stroke. Additionally, dur-
ing follow -up, there were 3 cases of thrombo-
embolic events. This translates into an 80.1% 
thromboembolism risk reduction, as compared 
with the calculated stroke rate of 6.7% without 
the use of anticoagulation in patients with simi-
lar CHA2DS2-VASc scores. Our results are compa-
rable to other LAAO studies, including those em-
ploying endocardial and epicardial devices.6‑8,20,21
The  most common adverse event was se-
vere bleeding (including 2 fatal bleeding epi-
sodes) with an annual major bleeding rate of 
6.3%. The observed bleeding risk reduction was 
27.5%. Although the bleeding rate reported in 
our study is higher than in the EWOLUTION 
registry (2.3%)20 or Amplatzer study (2.3%),21 
comparisons must be made cautiously. In our 
study, the mean (SD) HAS -BLED score of 4.4 
(0.9) was significantly higher than reported in 
EWOLUTION and Amplatzer trials (2.3 [1.2] and 
3.3 [1.1], respectively).20,21 Secondly, our study 
population consisted of 69% of patients with 
a history of major bleeding and contraindica-
tions to OAC, a higher prevalence than report-
ed in other LAAO trials.6‑8,20,21,27 In patients with 
a high risk of bleeding, there is no safe pharma-
cological treatment to reduce the risk of throm-
boembolic events in the first 6 months after 
a procedure because of endocardial device epi-
thelization. In our study, nearly 40% of severe 
bleeding, including 1 fatal bleeding episode, was 
observed within the first 6 months, when pa-
tients were on DAPT as recommended by the de-
vice protocol. The rate of major bleeding over 
the next 18 months of follow -up was accept-
able in a population with a history of high bleed-
ing risk. This observation may be confirmed by 
a study in patients at high risk for major bleed-
ing (mean [SD] HAS -BLED, 3.5 [1.0]) where ma-
jor bleeding events following LAAO were not 
related to the device or procedure. Interesting-
ly, in clinical registry data for a larger group of 
patients, higher major bleeding rates were ob-
served in patients discharged on aspirin alone 
or no antithrombotic medications as compared 
with those on OAC.21
limitations This was a nonrandomized, ret-
rospective, observational single -center study. 
The major limitations in estimating the overall 
value of LAAO are the lack of a control group and 
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